Joseph R. Bertino

Joseph Rocco Bertino (born August 16, 1930) is a researcher in the cancer pharmacology program at Rutgers Cancer Institute of New Jersey and professor of medicine and pharmacology at the Robert Wood Johnson Medical School in New Jersey. His research is focused on the treatment of lymphoma.

Joseph R. Bertino
Born (1930-08-16) August 16, 1930
Port Chester, New York, U.S.
Alma mater
Spouse(s)Mary (d. 2011)
Children4
Scientific career
Institutions

Early life and education

Bertino was born in Port Chester, New York as the youngest son of Joseph and Mamie Bertino. His parents immigrated from Italy shortly before World War I.[1]

After graduating from medical school at SUNY Downstate College of Medicine in 1954, Bertino did a USPHS fellowship in hematology and oncology at the University of Washington School of Medicine. In 1958, he moved to Seattle to work with Clement A. Finch and Frank M. Huennekens.[1]

He has four children with his wife, Mary, who died in 2011.[1]

Career

From 1973 to 1975, Bertino was the director of the Yale Cancer Center, until he was made an American Cancer Society Research Professor. He remained at Yale until 1987.[1] Following this, he was the chair of the Molecular Pharmacology and Therapeutics Program at Memorial Sloan-Kettering until 2002, when he moved to the Cancer Institute of New Jersey.[2][3]

Some of Bertino's notable scientific accomplishments are research into methotrexate and resistance to cancer treatments, including that use of methotrexate leads to an increase in dihydrofolate reductase. He is a founding editor of the Journal of Clinical Oncology.[2]

Awards
  • 1975 President of the American Society for Clinical Oncology
  • 1976-1979 Member, AACR Board of Directors
  • 1978 AACR–Richard and Hinda Rosenthal Award
  • 1992 David A. Karnofsky Memorial Award (American Society of Clinical Oncology)
  • 1995-1996 President of the American Association for Cancer Research
  • 2004 Freundlich Leadership Award (Lymphoma Research Foundation)
  • 2006 Key to the Cure Award (Lymphoma Research Foundation)
  • 2007 Bob Pinedo Cancer Care Prize for Contributions to Improvements in Cancer Care
  • 2007 ASCO Statesman Award[4]
  • 2008 John Ultman Award for Contributions to Lymphoma Research
  • 2008 AACR–Joseph H. Burchenal Memorial Award
  • 2011 Jeffrey A. Gottlieb Memorial Award (MD Anderson Cancer Center)
  • 2013 Elected fellow of the AACR Academy[2]
  • 2018 AACR Award for Lifetime Achievement in Cancer Research
gollark: No, he added AutoBotRobot, which is an even better decision.
gollark: DO NOT read the file. Your sanity will not survive.
gollark: Observe, the Autobias algorithm.
gollark: ++choose 1000 B C P L
gollark: ?choose B C P L

References
  1. "Dr. Joseph Bertino's Breakthrough Work in Methotrexate Resistance Led to Understanding Why Cancer Drugs Work or Fail - The ASCO Post". www.ascopost.com.
  2. "Joseph R. Bertino, MD".
  3. Chabner, Bruce A. (1 October 2008). "Dr. Joseph R. Bertino: A Reflection". The Oncologist. pp. 1034–1035. doi:10.1634/theoncologist.2008-0211.
  4. "Physician Profile | Rutgers Cancer Institute of New Jersey". www.cinj.org. Archived from the original on 2018-04-24. Retrieved 2018-04-23.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.